Adis Journals
Browse
dostarlimab-summary-slide.PNG (134.37 kB)

Dostarlimab: First Approval

Download (134.37 kB)
Version 3 2021-07-19, 19:15
Version 2 2021-06-16, 21:17
Version 1 2021-06-11, 03:54
online resource
posted on 2021-07-19, 19:15 authored by Anthony Markham

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.


Additional information about this Adis Drug Review can be found here.


Abstract


Dostarlimab (Jemperli™; GlaxoSmithKline) is a humanized monoclonal antibody programmed death-1 (PD-1) receptor antagonist being developed for the treatment of various cancers. Based on preliminary results from the GARNET trial dostarlimab has recently been approved in the EU and USA for the treatment of adult patients with mismatch repair deficient recurrent or advanced endometrial cancer. This article summarizes the milestones in the development of dostarlimab leading to these first approvals.


© Springer Nature Switzerland AG 2021

History

Usage metrics

    Drugs

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC